Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: ziprasidone; Drug
Lead sponsor: Bronx Psychiatric Center; Government
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Buffalo, New York • The Bronx, New York

Conditions: Schizophrenia
Interventions: Placebo, Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 50
States / cities: Phoenix, Arizona • Rogers, Arkansas • Anaheim, California + 39 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Risperidone, Exposure/ritual prevention therapy (EX/RP), Placebo; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Normal Non-fluency
Interventions: Olanzapine; Drug
Lead sponsor: Michael Rickels; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Aripiprazole, Risperidone; Drug
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Schizophrenia
Interventions: ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
Interventions: Pioglitazone, Life style diet group, Placebo; Drug · Behavioral · Other
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: ALK3831, Olanzapine, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 13 more

Conditions: Schizophrenia
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 22
States / cities: Cerritos, California • Chula Vista, California • Costa Mesa, California + 17 more

Conditions: Psychotic Disorders
Interventions: Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 19 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina

Conditions: Autism, Aggression, Bipolar Disorder, Psychotic Disorders
Interventions: Family Navigator consultation; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 2 Years to 15 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 4
States / cities: Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more

Conditions: Delirium, Cognitive Impairment
Interventions: Reduced exposure to anticholinergics, Reduced exposure to benzodiazepines, Haloperidol, Usual care; Behavioral · Procedure · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Post Traumatic Stress Disorder
Interventions: Quetiapine Fumarate, Standard of care meducations; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Parkinson Disease Psychosis
Interventions: Real-world, non-interventional; Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 69
States / cities: Cullman, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 62 more

Conditions: Schizophrenia
Interventions: SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more

Conditions: Delirium
Interventions: olanzapine, placebo; Drug
Lead sponsor: The New England Baptist Hospital; Other
Eligibility: 65 Years and older
Enrollment: 495 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI); Behavioral · Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 39
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Carson, California + 30 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Lurasidone HCl; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 27
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 21 more

Conditions: Bipolar Disorder
Interventions: lurasidone, Placebo; Drug · Other
Lead sponsor: Lakshmi N Yatham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Cleveland, Ohio

Conditions: Mental Health, Psychotic Disorders
Interventions: Evidence-Based Quality Improvement Plus Facilitation; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: North Little Rock, Arkansas

Conditions: Patients Prescribed Clozapine
Interventions: MyCare Insite Clozapine Test; Device
Lead sponsor: Saladax Biomedical, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Search by objective public record fields.

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder

Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

The Family VOICE Study

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Pharmacological Management of Delirium

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

Long-term Study of Cariprazine in Patients With Schizophrenia

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Monitoring and Management for Metabolic Side Effects of Antipsychotics

Clozapine Therapy Sample Collection - Method Comparison Study